Clinical Trials Directory

Trials / Conditions / Stage III Colon Cancer AJCC v8

Stage III Colon Cancer AJCC v8

17 registered clinical trials studyying Stage III Colon Cancer AJCC v8 — 5 currently recruiting.

StatusTrialSponsorPhase
RecruitingZanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for
NCT07405476
Emory UniversityPhase 2
Not Yet RecruitingFamily Communications After Genetic Testing
NCT07143487
Alliance for Clinical Trials in OncologyN/A
RecruitingImmunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB
NCT07140679
Emory UniversityPhase 2
WithdrawnBotensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Met
NCT06575725
City of Hope Medical CenterPhase 2
RecruitingDesigning a Dyad-Based mHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Ca
NCT06746012
Ohio State University Comprehensive Cancer CenterN/A
Active Not RecruitingTesting the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
NCT05710406
Alliance for Clinical Trials in OncologyPhase 2 / Phase 3
Active Not RecruitingTesting the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorecta
NCT05308446
National Cancer Institute (NCI)Phase 2
RecruitingTesting the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu
NCT04704661
National Cancer Institute (NCI)Phase 1
Active Not RecruitingLY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastat
NCT04616183
M.D. Anderson Cancer CenterPhase 1 / Phase 2
Active Not RecruitingSX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the S
NCT04599140
M.D. Anderson Cancer CenterPhase 1 / Phase 2
CompletedRegorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metast
NCT04362839
City of Hope Medical CenterPhase 1
Active Not RecruitingPanitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type C
NCT03992456
Academic and Community Cancer Research UnitedPhase 2
TerminatedGenetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Tr
NCT03765736
Academic and Community Cancer Research United—
CompletedTAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Ca
NCT04109924
Roswell Park Cancer InstitutePhase 2
TerminatedSavolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
NCT03592641
National Cancer Institute (NCI)Phase 2
Active Not RecruitingFinancial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment
NCT03516942
ECOG-ACRIN Cancer Research Group—
Active Not RecruitingCombination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Def
NCT02912559
National Cancer Institute (NCI)Phase 3